SEC Form 4 · accession 0000882104-18-000129
PDL BIOPHARMA, INC. · PDLI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Christopher Lewis Stone
Officer — VP, Gen. Counsel & Secretary
Period of report
Dec 27, 2018
Accepted (ET)
Dec 28, 2018 · 6:29 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000882104
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common stock | Dec 27, 2018 | F | 3,581 | $3.02 | D | 427,206 | D | |
| Common stockF1 | Dec 27, 2018 | D | 228,255 | $0.00 | D | 198,951 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Disposition of common stock due to performance criteria not being achieved under equity incentive plans.